title: Prevention of Respiratory Syncytial Virus Infection: From Vaccine to Antibody.
abstract: Respiratory syncytial virus (RSV) is the leading cause of lower respiratory tract disease in infants and young children. Initial efforts to develop a vaccine to prevent RSV lower respiratory tract disease in children were halted because of serious adverse events that occurred when children were infected with RSV following vaccination, including vaccine-related deaths. Subsequently, a major focus for researchers was to understand what led to these adverse events. Investment in a vaccine for RSV continues, and new strategies are under development. Success to prevent RSV disease was met by the development of immunoprophylaxis, first with intravenous immunoglobulin and then with recombinant monoclonal antibody. The story of immunoprophylaxis for RSV includes the first-in-class use of antibody technology for infectious disease, and palivizumab currently remains the only way to prevent serious lower respiratory tract disease due to RSV infection.
authors.affiliation: Department of Infectious Disease, MedImmune, LLC., One MedImmune Way, Gaithersburg, MD 20878.
authors.forename: Kelly
authors.initials: K
authors.lastname: Huang
authors.forename: Herren
authors.initials: H
authors.lastname: Wu
mesh_terms: D000911:Antibodies, Monoclonal / Q000276:immunology / Q000627:therapeutic use; D000914:Antibodies, Viral / Q000276:immunology* / Q000627:therapeutic use*; D018890:Chemoprevention / Q000379:methods; D006801:Humans; D016756:Immunoglobulins, Intravenous / Q000276:immunology / Q000627:therapeutic use; D000069455:Palivizumab / Q000276:immunology / Q000627:therapeutic use; D018357:Respiratory Syncytial Virus Infections / Q000517:prevention & control*; D022261:Respiratory Syncytial Virus Vaccines / Q000008:administration & dosage / Q000009:adverse effects / Q000276:immunology*; D012136:Respiratory Syncytial Viruses / Q000276:immunology; D014611:Vaccination / Q000379:methods*
chemical_list: D000911:Antibodies, Monoclonal; D000914:Antibodies, Viral; D016756:Immunoglobulins, Intravenous; D022261:Respiratory Syncytial Virus Vaccines; D000069455:Palivizumab